Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects

Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have focused on immunotherapy for HCC. Immunotherapies have shown promising clinical outcomes in several types of cancers a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Cheng, Li, Yirun, Yang, Jing, Jin, Shengxi, Chen, Guoqiao, Li, Duguang, Fan, Xiaoxiao, Lin, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039369/
https://www.ncbi.nlm.nih.gov/pubmed/33854960
http://dx.doi.org/10.3389/fonc.2021.589680
Descripción
Sumario:Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have focused on immunotherapy for HCC. Immunotherapies have shown promising clinical outcomes in several types of cancers and potential therapeutic effects for advanced HCC. In this review, we summarize the immune tolerance and immunotherapeutic strategies for HCC as well as the main challenges of current therapeutic approaches. We also present alternative strategies for overcoming these limitations.

Ejemplares similares